Currently Enrolling
Clinical trials for patients with urothelial carcinoma or advanced solid tumors1-4
Explore how enfortumab vedotin (EV)—an antibody-drug conjugate—is being studied alone and with other therapies.1-5
Actor portrayal.
Actor portrayal.
EV+pembrolizumab combination therapy
EV monotherapy
The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy have not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.
BCG=Bacillus Calmette-Guérin; EV=enfortumab vedotin; la/mUC=locally advanced or metastatic urothelial cancer; MIBC=muscle-invasive bladder cancer; MOA=mechanism of action; NMIBC=non–muscle-invasive bladder cancer.
References: 1. ClinicalTrials.gov. Perioperative pembrolizumab (MK-3475) plus cystectomy or perioperative pembrolizumab plus enfortumab vedotin plus cystectomy versus cystectomy alone in participants who are cisplatin-ineligible or decline cisplatin with muscle-invasive bladder cancer (MK-3474-905/KEYNOTE-905/EV-303) (07-14-2022). https://clinicaltrials.gov/ct2/show/nct03924895. Accessed 07-14-2022. 2. ClinicalTrials.gov. Perioperative enfortumab vedotin (EV) plus pembrolizumab (MK-3475) versus neoadjuvant chemotherapy for cisplatin-eligible muscle invasive bladder cancer (MIBC) (MK-3475-B15/KEYNOTE-B15/EV-304) (KEYNOTE-B15) (01-07-2021). https://clinicaltrials.gov/ct2/show/nct04700124. Accessed 04-18-2022. 3. ClinicalTrials.gov. A study to evaluate enfortumab vedotin in subjects with previously treated locally advanced or metastatic malignant solid tumors (EV-202) (01-13-2020). https://clinicaltrials.gov/ct2/show/nct04225117. Accessed 04-18-2022. 4. ClinicalTrials.gov. A study of intravesical enfortumab vedotin for treatment of patients with non-muscle invasive bladder cancer (NMIBC) (08-20-2021). https://clinicaltrials.gov/ct2/show/nct05014139. Accessed 04-18-2022. 5. Rosenberg J, O’Donnell PH, Balar AV, et al. Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy. J Clin Oncol 2019;37(29):2592-600.
